These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

631 related items for PubMed ID: 25910495

  • 1. Phosphate, fibroblast growth factor 23 and retinopathy in chronic kidney disease: the Chronic Renal Insufficiency Cohort Study.
    Mehta R, Ying GS, Houston S, Isakova T, Nessel L, Ojo A, Go A, Lash J, Kusek J, Grunwald J, Wolf M, CRIC Study Investigators.
    Nephrol Dial Transplant; 2015 Sep; 30(9):1534-41. PubMed ID: 25910495
    [Abstract] [Full Text] [Related]

  • 2. FGF23 and Left Ventricular Hypertrophy in Children with CKD.
    Mitsnefes MM, Betoko A, Schneider MF, Salusky IB, Wolf MS, Jüppner H, Warady BA, Furth SL, Portale AA.
    Clin J Am Soc Nephrol; 2018 Jan 06; 13(1):45-52. PubMed ID: 29025789
    [Abstract] [Full Text] [Related]

  • 3. Impact of fractional phosphate excretion on the relation of FGF23 with outcome in CKD patients.
    Bech AP, Bouma-de Krijger A, van Zuilen AD, Bots ML, van den Brand JA, Blankestijn PJ, Wetzels JF, Vervloet MG.
    J Nephrol; 2015 Aug 06; 28(4):477-84. PubMed ID: 25700931
    [Abstract] [Full Text] [Related]

  • 4. Fibroblast growth factor 23 and new-onset chronic kidney disease in the general population: the Prevention of Renal and Vascular Endstage Disease (PREVEND) study.
    De Jong MA, Eisenga MF, van Ballegooijen AJ, Beulens JWJ, Vervloet MG, Navis G, Gansevoort RT, Bakker SJL, De Borst MH.
    Nephrol Dial Transplant; 2021 Jan 01; 36(1):121-128. PubMed ID: 32124925
    [Abstract] [Full Text] [Related]

  • 5. Fibroblast growth factor 23 and markers of mineral metabolism in individuals with preserved renal function.
    Dhayat NA, Ackermann D, Pruijm M, Ponte B, Ehret G, Guessous I, Leichtle AB, Paccaud F, Mohaupt M, Fiedler GM, Devuyst O, Pechère-Bertschi A, Burnier M, Martin PY, Bochud M, Vogt B, Fuster DG.
    Kidney Int; 2016 Sep 01; 90(3):648-57. PubMed ID: 27370409
    [Abstract] [Full Text] [Related]

  • 6. Fibroblast Growth Factor 23 and Risk of CKD Progression in Children.
    Portale AA, Wolf MS, Messinger S, Perwad F, Jüppner H, Warady BA, Furth SL, Salusky IB.
    Clin J Am Soc Nephrol; 2016 Nov 07; 11(11):1989-1998. PubMed ID: 27561289
    [Abstract] [Full Text] [Related]

  • 7. Inflammation and elevated levels of fibroblast growth factor 23 are independent risk factors for death in chronic kidney disease.
    Munoz Mendoza J, Isakova T, Cai X, Bayes LY, Faul C, Scialla JJ, Lash JP, Chen J, He J, Navaneethan S, Negrea L, Rosas SE, Kretzler M, Nessel L, Xie D, Anderson AH, Raj DS, Wolf M, CRIC Study Investigators.
    Kidney Int; 2017 Mar 07; 91(3):711-719. PubMed ID: 28017325
    [Abstract] [Full Text] [Related]

  • 8. Progression of arterial stiffness is associated with changes in bone mineral markers in advanced CKD.
    Krishnasamy R, Tan SJ, Hawley CM, Johnson DW, Stanton T, Lee K, Mudge DW, Campbell S, Elder GJ, Toussaint ND, Isbel NM.
    BMC Nephrol; 2017 Sep 04; 18(1):281. PubMed ID: 28870151
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effects of Nicotinamide and Lanthanum Carbonate on Serum Phosphate and Fibroblast Growth Factor-23 in CKD: The COMBINE Trial.
    Ix JH, Isakova T, Larive B, Raphael KL, Raj DS, Cheung AK, Sprague SM, Fried LF, Gassman JJ, Middleton JP, Flessner MF, Block GA, Wolf M.
    J Am Soc Nephrol; 2019 Jun 04; 30(6):1096-1108. PubMed ID: 31085679
    [Abstract] [Full Text] [Related]

  • 11. Applicability of fibroblast growth factor 23 for evaluation of risk of vertebral fracture and chronic kidney disease-mineral bone disease in elderly chronic kidney disease patients.
    Kanda E, Yoshida M, Sasaki S.
    BMC Nephrol; 2012 Sep 26; 13():122. PubMed ID: 23013306
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Associations of fibroblast growth factor 23, vitamin D and parathyroid hormone with 5-year outcomes in a prospective primary care cohort of people with chronic kidney disease stage 3.
    Shardlow A, McIntyre NJ, Fluck RJ, McIntyre CW, Taal MW.
    BMJ Open; 2017 Aug 23; 7(8):e016528. PubMed ID: 28838895
    [Abstract] [Full Text] [Related]

  • 15. Effect of a non-calcium-based phosphate binder on fibroblast growth factor 23 in chronic kidney disease.
    Spatz C, Roe K, Lehman E, Verma N.
    Nephron Clin Pract; 2013 Aug 23; 123(1-2):61-6. PubMed ID: 23774446
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.